SkinHealth Systems Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SKIN$15.94-4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(10,187) | $(1,415) |
| Adjustments to reconcile net loss to net cash from operating activities | ||
| Share-based compensation | 6,416 | 11,239 |
| Amortization of intangible assets | 10,538 | 13,513 |
| Depreciation of property and equipment | 1,644 | 3,204 |
| Amortization of other assets | 3,693 | 3,281 |
| Amortization of debt issuance costs | 2,989 | 2,621 |
| Inventory write-down | 1,625 | 3,643 |
| Provision for estimated credit losses | 1,397 | 1,933 |
| Change in fair value of warrant liabilities | — | (349) |
| Gain on exchange and repurchases of convertible senior notes, net | (1,019) | (18,089) |
| Deferred income taxes | 65 | 2,893 |
| Other, net | 4,738 | (2,679) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,763 | 4,769 |
| Inventories | (160) | 11,114 |
| Prepaid expenses, other current assets, and income tax receivable | (17,450) | (110) |
| Accounts payable, accrued expenses, and income tax payable | 8,472 | (7,117) |
| Other, net | (6,144) | (6,162) |
| Net cash provided by operating activities | 8,380 | 22,289 |
| Cash flows from investing activities: | ||
| Cash paid for intangible assets | (3,173) | (3,617) |
| Cash paid for property and equipment | (744) | (164) |
| Net cash used for investing activities | (3,917) | (3,781) |
| Cash flows from financing activities: | ||
| Repayment of 2026 Notes | (103,235) | — |
| Repurchase of 2026 Notes | (20,161) | (18,372) |
| Payment of tax withholdings on vested stock awards | (1,241) | (1,145) |
| Repurchase of 2026 Notes in connection with exchange | — | (392,583) |
| Issuance of 2028 Notes in connection with exchange, net | — | 237,686 |
| Net cash used for financing activities | (124,637) | (174,414) |
| Net change in cash, cash equivalents, and restricted cash | (120,174) | (155,906) |
| Effect of foreign currency translation on cash | (113) | 5,240 |
| Cash, cash equivalents, and restricted cash beginning of period | 232,673 | 370,063 |
| Cash, cash equivalents, and restricted cash end of period | $112,386 | $219,397 |
The accompanying notes are an integral part of these unaudited financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.